Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S102-S108
DOI: 10.4103/ijmpo.ijmpo_206_17
Original Article

Outcomes of Breast Cancer Management from an Urban Specialist Breast Center in South India

Naga Amulya Mullapudi
Department of Oncoplastic Breast Surgery, Chennai Breast Centre, Chennai, Tamil Nadu, India
,
Kabeer Katherine Kirti
Department of Oncoplastic Breast Surgery, Chennai Breast Centre, Chennai, Tamil Nadu, India
,
Naveen Padmanaban
Department of Surgical Oncology, AIIMS, New Delhi, India
,
Ramesh Nimmagadda
Department of Medical Oncology, Apollo Speciality Hospital, Chennai, Tamil Nadu, India
,
Selvi Radhakrishna
Department of Oncoplastic Breast Surgery, Chennai Breast Centre, Chennai, Tamil Nadu, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Context and Aims: The disease pattern and presentation of breast cancer in India are thought to differ from the West. The purpose of this study is to describe and to discuss the presentation, clinicopathological data, and survival from an urban specialist breast center in Southern India. Materials and Methods: Prospectively collected data were analyzed for clinicopathological details, treatment variables, and survival outcomes were analyzed. Cumulative survival curves were estimated using the Kaplan–Meier method for patients treated from 2007 to 2011. Results: A total of 1671 patients were operated at our center from January 2007 to December 2016. Average age at diagnosis was 54.2 years. Over 70% had Stage I and Stage II disease, infiltrating duct carcinoma was predominant in 88.2%. Average clinical tumor size was three centimeters. Breast conservation was performed in 22.4%. Sentinel lymph node biopsy was performed in 44.6%. Estrogen-receptor positivity was seen in 64.6%, 22.2% were Her2Neu positive. Triple negative disease was seen in 19.1%. Survival analysis was done using the Kaplan–Meier curves for 540 patients treated from 2007 to 2011. The median follow-up of surviving patients was 70 months with 10% lost to follow-up. In our study population, the 5 years overall survival rate is 88.3% and disease-free survival is 85.7%. Conclusion: Our study reflects a higher percentage of early breast cancer with outcomes comparable to the West. More research is required to understand the genetic predisposition in our population.

Keywords

Breast cancer - breast cancer in India - breast cancer management - breast cancer outcomes - specialist breast center


Publication History

Article published online:
24 May 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Khokhar A. Breast cancer in India: Where do we stand and where do we go?. Asian Pac J Cancer Prev 2012; 13: 4861-6
    CrossrefPubMedGoogle Scholar
  • 2 Agarwal G, Ramakant P. Breast cancer care in India: The current scenario and the challenges for the future. Breast Care (Basel) 2008; 3: 21-7
    CrossrefPubMedGoogle Scholar
  • 3 Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007; 31: 1031-40
    CrossrefPubMedGoogle Scholar
  • 4 ICMR Subcommittee on Breast Cancer. Consensus Document for Management of Breast Cancer. 2016: 2016
    PubMedGoogle Scholar
  • 5 Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani C, Murthy NS. et al. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India – A cross-sectional study. World J Surg Oncol 2005; 3: 67
    CrossrefPubMedGoogle Scholar
  • 6 Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, Nair MK. et al. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther 2002; 1: 18-21
    CrossrefPubMedGoogle Scholar
  • 7 Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V, Shanta V. et al. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev 2003; 4: 203-8
    PubMedGoogle Scholar
  • 8 Valarmathi MT, Sawhney M, Deo SS, Shukla NK, Das SN. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Hum Mutat 2004; 23: 205
    CrossrefPubMedGoogle Scholar
  • 9 Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R. et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: Methodology and interim results after three rounds of screening. Int J Cancer 2010; 126: 976-84
    PubMedGoogle Scholar
  • 10 Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Prabhakar J, Augustine P. et al. Clinical breast examination: Preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 2011; 103: 1476-80
    CrossrefPubMedGoogle Scholar
  • 11 van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC. et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: A population-based study. Lancet Oncol 2016; 17: 1158-70
    CrossrefPubMedGoogle Scholar
  • 12 Parmar V, Hawaldar R, Nair NS, Shet T, Vanmali V, Desai S. et al. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer. Breast 2013; 22: 1081-6
    CrossrefPubMedGoogle Scholar
  • 13 Somashekhar SP, Zaveri Shabber S, Udupa Venkatesh K, Venkatachala K, Parameswaran RV, Vasan Thirumalai MM. et al. Sentinel lymphnode biopsy in early breast cancer using methylene blue dye and radioactive sulphur colloid – A single institution Indian experience. Indian J Surg 2008; 70: 111-9
    CrossrefPubMedGoogle Scholar
  • 14 Dinshaw KA, Budrukkar AN, Chinoy RF, Sarin R, Badwe R, Hawaldar R. et al. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2005; 63: 1132-41
    CrossrefPubMedGoogle Scholar
  • 15 Rangarajan B, Shet T, Wadasadawala T, Nair NS, Sairam RM, Hingmire SS. et al. Breast cancer: An overview of published Indian data. South Asian J Cancer 2016; 5: 86-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P. et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011; 48: 391-6
    CrossrefPubMedGoogle Scholar
  • 17 Manjunath S, Prabhu JS, Kaluve R. Estrogen receptor negative breast cancer in India : Do we really have higher burden of this subtype Indian. J Surg Oncol 2011; 2: 122-5
    Google Scholar
  • 18 Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu YS. et al. Management of HER2-positive breast cancer in Asia: Consensus statement from the Asian oncology summit 2009. Lancet Oncol 2009; 10: 1077-85
    CrossrefPubMedGoogle Scholar
  • 19 Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triple-negative breast cancer in India: Systematic review and meta-analysis. J Glob Oncol 2016; 2: 412-21
    CrossrefPubMedGoogle Scholar
  • 20 Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ. et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20: 1071-82
    CrossrefPubMedGoogle Scholar
  • 21 Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K. et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006; 295: 2492-502
    CrossrefPubMedGoogle Scholar
  • 22 Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK. Triple-negative breast cancer: An institutional analysis. Indian J Cancer 2014; 51: 163-6
    CrossrefPubMedGoogle Scholar
  • 23 Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V. et al. Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: Does the survival vary for all stages?. World J Surg 2016; 40: 1362-72
    CrossrefPubMedGoogle Scholar
  • 24 Badwe R, Hawaldar R, Parmar V, Nadkarni M, Shet T, Desai S. et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: A randomized controlled trial. J Clin Oncol 2011; 29: 2845-51
    CrossrefPubMedGoogle Scholar
  • 25 EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). McGale P, Taylor C, Correa C, Cutter D, Duane F. et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383: 2127-35
    CrossrefPubMedGoogle Scholar
  • 26 START Trialists’ Group. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ. et al. The UK standardisation of breast radiotherapy (START) trial a of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 2008; 9: 331-41
    CrossrefPubMedGoogle Scholar
  • 27 Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L. et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002; 94: 1143-50
    CrossrefPubMedGoogle Scholar